Development of Keap1 gene therapy for chemo-resistance endometrial cancer.

• Project/Area Number: 24592500
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Tohoku University
• Principal Investigator: YOSHINAGA Kousuke 東北大学, 医学(系)研究科(研究院), 非常勤講師 (40343058)
• Co-Investigator(Kenkyū-buntansha): NAGASE Satoru 山形大学, 医学部, 教授 (00292326) ; TAKANO Tadao 東北大学, 病院, 特任教授 (40282058)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000); Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000); Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 子宮内膜癌 / 化学療法抵抗性 / Keap1遺伝子 / Nrf2遺伝子 / 遺伝子治療 / Keapl遺伝子

Outline of Final Research Achievements

Mutation of Keap1 and Nrf2 genes has been implicated in chemo- and radiation-resistance in multiple types of cancer. In this study, we uncovered involvement of the gene mutation in chemo-resistance endometrial cancer and established the human Keap1 expression vector. Moreover, microRNA-34b was also revealed to play a key role in proliferation, invasion and progression of cancer. Those results would promote to develop the Keap1 genetherapy for chemo-resistance endometrial cancer.

Research Products

• [Presentation] MiR-34b correlates tumor growth and invasion in uterine serous carcinoma. (2015)
  • Author(s): Suzuki F, Nagase S, Watanabe Y, Sato I, Utsunomiya H, Kaiho M, Tokunaga H, Niikura H, Takano T, Sasano H, Yaegashi N.
  • Organizer: 62nd Annual Meeting of SRI (Society of Reproductive Investigation).
  • Place of Presentation: San Francisco（USA)
  • Year and Date: 2015-03-26